Category Archives: Neurotechnology

The report provides an in-depth analysis of the Global Market of Neural Control. It presents the latest data of the market value, consumption, domestic production, exports and imports, and price dynamics. The Neural Control market report shows the sales data, allowing you to identify the key drivers and restraints. You can find here a strategic analysis of key factors influencing the market. Forecasts illustrate how the market will be transformed in the medium term. Profiles of the leading players like MIT, Hebrew university, Haier, Neurotechnology,,, etc. are also included.

Data Coverage in Neural Control Market Report are:

Get Premium Quality Sample copy of Neural Control Market Report at: https://www.affluencemarketreports.com/industry-analysis/request-sample/2377741/

The Key Players Covered in Neural Control Market Study are:

Segmentation Analysis:

Neural Control market is split by Type and by Application. For the period 2016-2028, the growth among segments provides accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market Segmentation by Type:

Market Segmentation by Applications:

For more Customization in this Report, Connect with us at https://www.affluencemarketreports.com/industry-analysis/request-inquiry/2377741/

The report offers valuable insight into the Neural Control market progress and approaches related to the Neural Control market with an analysis of each region. The report goes on to talk about the dominant aspects of the market and examine each segment.

The Neural Control market report gives CAGR value, Industry Chains, Upstream, Geography, End-user, Application, Competitor analysis, SWOT Analysis, Sales, Revenue, Price, Gross Margin, Market Share, Import-Export, Trends, and Forecast. The report also gives insight into the entry and exit barriers of the industry.

Global Neural Control Market Report Scope:

The report offers a complete company profiling of leading players competing in the global Neural Control market with a high focus on the share, gross margin, net profit, sales, product portfolio, new applications, recent developments, and several other factors. It also throws light on the vendor landscape to help players become aware of future competitive changes in the global Neural Control market.

Target Audience of the Global Neural Control Market in Market Study:

Get Extra Discount on Neural Control Market Report, If your Company is Listed in Above Key Players List @ https://www.affluencemarketreports.com/industry-analysis/request-discount/2377741/

Major Points from Table of Contents

For More Details on Impact of COVID-19 on Neural Control Market: https://www.affluencemarketreports.com/industry-analysis/covid19-request/2377741/

About Affluence:

Affluence Market Reports is the next generation of all your research needs with a strong grapple on the worldwide market for industries, organizations, and governments. Our aim is to deliver exemplary reports that meet the definite needs of clients, which offers an adequate business technique, planning, and competitive landscape for new and existing industries that will develop your business needs.

We provide a premium in-depth statistical approach, a 360-degree market view that includes detailed segmentation, key trends, strategic recommendations, growth figures, Cost Analysis, new progress, evolving technologies, and forecasts by authentic agencies.

For More Details Contact Us:

Affluence Market Reports

Contact Person: Mr. Rohit

Phone Number: U.S +1-(424) 256-1722

Email: [emailprotected]

Website: http://www.affluencemarketreports.com

Visit link:

Futuristics Overview of Neural Control Market: Industry Insights and Forecast 2022-2028 by MIT, Hebrew university, Haier, Neurotechnology,,, and more...

Market Research Future

Emerging BCI Implantable Solutions Improve Human Lives

New York US, May 02, 2022 (GLOBE NEWSWIRE) -- Brain Computer Interface Market Overview: According to a comprehensive research report by Market Research Future (MRFR), Brain Computer Interface Market information by Type, by Components, by End-User and Region Forecast to 2030 market size to reach USD 5.48 billion, growing at a compound annual growth rate of 14.72% by 2030.

BCI Market Scope: The global brain computer interface market is growing rapidly. Rapid adoption of these systems in communication and control applications is a major driving force. Initially developed for improving the quality of life of physically impaired and elderly patients, the brain-computer interface technology is now used as a neurofeedback training tool to improve cognitive performance.

Brain-computer interface (BCI) technology is slowly moving into the mass market, finding applications in measuring central nervous system (CNS) activities in the human body. BCI systems can also convert activities of the central nervous system into electrical signals, used as artificial outputs to restore, enhance, replace, supplement, or improve natural CNS output, changing the interactions between the CNS and its external/ internal environment.

Dominant Key Players on Brain Computer Interface Market Covered are:

Get Free Sample PDF Brochure: https://www.marketresearchfuture.com/sample_request/8412

Market USP Exclusively Encompassed:Brain Computer Interface Market DriversThe early adoption of BCI technology in various industries and high investments by governments to promote BCI technology applications across military & aerospace sectors are key market trends. Besides, investments by major industry providers in developing advanced BCI systems impact the market growth positively. BCI devices are increasingly used in treating many patients suffering from cognitive or physical impairments.

Story continues

This technology promises greater improvements in the quality of life of physically impaired people, enhancing their autonomy and mobility. High investments in technology upgrades and funding to implement BCI devices in the healthcare sectors boost the market size. On the other hand, the ethical challenges of connecting brains to computers impede market growth.

Currently, implantable BCIs are extensively used to restore functions in people with paralysis and neurological disorders. BCI hardware and technology are used by patients using the neurotechnology to restore movement, communication, and touch to increase independence and quality of life.

Browse In-depth Market Research Report (126 Pages) on Brain Computer Interface Market: https://www.marketresearchfuture.com/reports/brain-computer-interface-market-8412

Segmentation of Market Covered in the Research:The BCI market report is segmented into components, types, applications, technologies, end-users, and regions. The type segment comprises non-invasive, invasive, and partially invasive. The component segment comprises hardware and software. The application segment comprises medical, communication & control, gaming & virtual reality, smart home control, and others.

The technology segment comprises electroencephalography (EEG), magnetoencephalography (MEG), electrocorticography (ECoG), functional magnetic resonance imaging (fMRI), near-infrared spectroscopy (NIRS), intracortical neuro recording, and others.

The end-user segment comprises healthcare, education & research, defense and aerospace, and others. The region segment comprises the Middle East & Africa, Americas, Asia Pacific, Europe, and Rest-of-the-World.

Talk to Expert: https://www.marketresearchfuture.com/ask_for_schedule_call/8412

Regional AnalysisNorth America dominates the global brain computer interface market. The rising demand for advanced BCI technologies from healthcare, education & research, and defense & aerospace industries drives the market growth. Besides, the large presence of technology providers and medical & non-medical device manufacturers in this region boosts the BCI market size.

Among other North American countries, The US accounts for the largest share in the regional market, heading with the large pool of market players and investors in the BCI technology.

Europe seizes the second-largest share in the global brain computer interface market. Factors such as the increasing adoption of BCI devices and rising applications of BCI software in various hospitals, universities, and research institutes substantiate the region's market share.

With the growing uptake of BCIs, Germany dominates the regional market, followed by the UK. Furthermore, France, Russia, Spain, Italy, Bulgaria, the Netherlands, and Sweden are also estimated to boost the market growth in Europe.

The Asia Pacific region holds a considerable market share, emerging as a significant market for brain computer interfaces globally. The growing adoption of BCI technologies among small- and medium-sized enterprises and rapid economic growth in this region propels market growth.

Buy this Report:https://www.marketresearchfuture.com/checkout?currency=one_user-USD&report_id=8412 Competitive LandscapeThe brain computer interface market appears extremely fragmented, considering the presence of established manufacturers. Eminent players seek opportunities to integrate across the extensive value chain while focusing on expanding production capacities, R&D investments, and M&A activities to gain additional impetus. They strive to deliver reliable, leading-edge brain computer interface technologies for various applications, substantially investing in developing adept technologies and products.

For instance, on Apr. 26, 2022, Blackrock Neurotech, a leading provider of brain-computer interface technology, announced a partnership with Phantom Neuro to enable prosthetics and exoskeletons that mimic human movement in real-time. Phantom Neuro is a neurotech startup recently launched by Blackrock Neurotech to deliver a high accuracy system for lifelike control of robotic orthopedic technologies.

Blackrock will become a research and development partner for Phantom Neuro's patent-pending Phantom X system, which offers highly accurate, nearly real-time control of current & next-generation assistive devices, including prosthetics and exoskeletons. The partnership would help accelerate Phantom X's research and development path to clinical trials.

On Apr. 22, 2022, Blackrock Neurotech announced the acquisition of MindX, a spatial computing software firm, to commercialize its brain-computer interface product. The company plans to integrate MindX's augmented reality (AR) and artificial intelligence (AI) technology with its BCI hardware. The acquisition would bolster Blackrock's existing software portfolio and enable it to deliver full-stack, integrated BCI products with innovative capabilities.

Related Reports:File Sharing Market Research Report: Information By Type (System Native, Client Server, Peer-To-Peer and Others), Deployment (Cloud and On-Premise), Services (Managed Services and Professional Services), End-User (Enterprise, Individual and Government), Vertical (BFSI, Healthcare, IT & Telecommunication, Education & Research, Media & Entertainment and Others) - Forecast till 2030

Independent Software Vendors (ISVs) Market Research Report: Information By Type (Cloud and On-Premise), Application (e-Commerce, Logistics, Retail, Healthcare, Financial, Education and Others) - Forecast to 2030

Antivirus Software Market Research Report: Information By Type (PC and Phones/Pad), By Application (Enterprises, Individual and Government) - Forecast till 2030

About Market Research Future:Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis regarding diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.

Follow Us: LinkedIn | Twitter

Go here to read the rest:

Brain Computer Interface (BCI) Market Poised to Garner a Valuation of USD 5.48 Billion by 2030, Growing at a 14.72% CAGR - Report by Market Research...

InSpace implant demonstrated to be a viable option for patients with massive irreparable rotator cuff tears.*

KALAMAZOO, Mich.,May 3, 2022/PRNewswire/ Stryker (NYSE:SYK) announced today the publication of results from a multicenter, single-blinded, randomized controlled trial comparing Strykers InSpace implant with partial repair for the treatment of full-thickness massive irreparable rotator cuff tears (MIRCTs) in theJournal of Bone and Joint Surgery (JBJS).

The comparative study evaluated the efficacy and safety of Strykers InSpace implant with arthroscopic partial repair in patients with irreparable, posterosuperior MIRCTs.

Results of the two-year study demonstrated the InSpace implant as an appropriate alternative to partial repair in patients with MIRCTs. The study also revealed notable patient benefits including early functional recovery and pain relief combined with a shorter operative time.

MIRCTs are one of the most common causes of shoulder dysfunction.1,2,3The InSpace balloon implant* is a breakthrough solution in the shoulder continuum of care that addresses MIRCTs and provides a new, simple surgical treatment option, allowing surgeons to better meet the needs of their patients.

We are excited to see the high-quality data from the U.S. InSpace trial accepted and published by one of the most prestigious orthopaedic journals, said the lead investigator in the clinical study,Nikhil Verma, M.D. These results demonstrating InSpace as a safe and effective option with earlier functional recovery, pain relief and shorter operative times are helping us change the game in shoulder surgery and creating better care for patients.

About the clinical studyThe purpose of the Level 1 InSpace pivotal study a prospective, single-blinded, multi-center, randomized, controlled trial was to assess the safety and effectiveness of the InSpace Implant (IS) compared to Partial Repair (PR). The study evaluated 184 (n=93 IS; n=91 PR) randomized eligible patients with symptomatic massive full thickness rotator cuff tears that failed non-operative management, through 24 months of follow-up.1

Click hereto read the full JBJS article on the study.

About the balloonInSpace is a biodegradable implant designed to restore the subacromial space, providing a less invasive solution compared to other surgical treatment options that require fixation devices or grafts and has been demonstrated to improve shoulder motion and function.4

More information about the InSpace balloon implant is available atwww.stryker.com/inspace.

About StrykerStryker is one of the worlds leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Medical and Surgical, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 100 million patients annually. More information is available atwww.stryker.com.

Media contactKara RasmussenSr. Director, Communications and PRkara.rasmussen@stryker.comPhone: 408 529 7512

1. Novi M, et al. Irreparable rotator cuff tears: challenges and solutions.Orthop Res Rev.2018; 10:93-103.2. Yamamoto A, et al. Prevalence and risk factors of a rotator cuff tear in the general population.J Shoulder Elbow Surg.2010; 19(1):116-120.3. Minagawa H, et al. Prevalence of symptomatic and asymptomatic rotator cuff tears in the general population: From mass-screening in one village.J Orthop.2013; 10(1):8-12.4. Verma N, Srikumaran U, Roden CM, Rogusky EJ, Lapner P, Neill H, Abboud JA. (2022). InSpace implant compared with partial repair for treatment of full-thickness massive rotator cuff tears. J Bone Joint Surg Am.Advance online publication. doi. 10.2106/JBJS.21.00667

*The InSpace subacromial tissue spacer system is indicated for the treatment of patients with massive, irreparable full-thickness torn rotator cuff tendons due to trauma or degradation with mild to moderate gleno-humeral osteoarthritis in patients greater than or equal to 65 years of age whose clinical conditions would benefit from treatment with a shorter surgical time compared to partial rotator cuff repair.

SOURCE Stryker

See the rest here:

Stryker's InSpace subacromial balloon spacer two-year, Level 1 randomized controlled clinical study published in the Journal of Bone and Joint Surgery...

Kalamazoo, May 02, 2022 (GLOBE NEWSWIRE) -- Stryker SYK will participate in the Bank of America Securities 2022 Health Care Conference on Wednesday, May 11, 2022.

Andy Pierce, Group President, MedSurg and Neurotechnology and Preston Wells, Vice President, Investor Relations will represent the Company in a presentation scheduled for 11:00 a.m. Eastern Time.

A simultaneous webcast and replay of the Company's presentation will be available on Stryker's website at http://www.stryker.com. The webcast will be archived on the Investor Relations page of this site.

Stryker is one of the world's leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Medical and Surgical, Neurotechnology, Orthopaedics and Spine that help improve patient and hospital outcomes. More information is available at http://www.stryker.com.

Here is the original post:

Stryker to participate in the Bank of America Securities 2022 Health Care Conference - Benzinga - Benzinga

As forecasted by Johnson & Johnson and Intuitive Surgical in the first week of earnings, medical device companies saw procedures bounce back after Januarys surge in COVID-19 cases. Still, several companies also reported not being able to meet all of the demand for products because of shortages of critical supplies or hospital staffing.

One of them was ResMed, which has been grappling with shortages of semiconductor chips for the last year as its competitor, Philips, undergoes a months-long recall of its Respironics ventilators and sleep-apnea devices.

Philips estimated another 300,000 devices will need to be added to the recall, which already encompasses more than 5 million. It also expects the process of replacing devices to continue into 2023. The recall has been continuing since June of last year.

In an April 25 investor call, CEO Frans van Houten said the company took an additional65 million euros provision, which was equal to about $70 million at the time of the announcement,related to the repair and replacement of the recalled devices, and another over $100 million to offset higher costs of executing the program, such as inflationary pressures. The companys stock dropped more than 15% on the news and amid a disclosure that the U.S. Department of Justice had subpoenaed Philips and its subsidiaries related to the recall.

Source: New York Stock Exchange

So far, Philips has only produced about 2.2 million repair kits or replacement devices, up from 1.5 million last year, analysts with KeyBanc Capital Markets wrote in a research note. However, the company said it had increased its pace of production despite supply chain challenges.

ResMed, which was expected to post a $300 million to $350 million benefit from its competitors recall, also hemmed in analysts expectations, citing shortages of critical components.

Specifically, ResMed CEO Mick Farrell said a semiconductor supplier had a very significant, double-digit de-commit.

Now, the company only expects to see a $200 million to $250 million benefit from the recall in the current fiscal year, which ends in June.

ResMed has cited supply chain challenges throughout the year as shortages of chips in particular have been a concern since 2020. Competing with makers of electric vehicles and consumer electronics, ResMed has taken to pitching manufacturers on its high margins and long-term contracts as well as the importance of the chips in helping people with breathing.

Whenever we talk to almost anyone in any industry, we end up talking to somebody who either has sleep apnea or their loved ones have sleep apnea or their good friends have sleep apnea. So we can get a really strong message through as to why it should be a priority, COO Rob Douglas said on an earnings call on April 28. But sometimes, they've got contracts and they need to be able to call force majeure on those contracts before they can supply us.

The patients are there. And I think it's awful that somebody might have to wait four weeks or eight weeks. I don't want them to wait more than four to eight hours. But right at the moment, we're in this situation; [it] will be that way for a period of time given these unprecedented circumstances.

One temporary solution for ResMed is to redesign its devices so that they dont use semiconductors. This was done with the companys AirSense 10 device, by removing the 3G or 4G chip, and instead letting providers upload the data from an SD card to their patient management system manually, as was done with the devices original manufacturing design.

Resmed also is working on retrieving more parts suppliers, finding new suppliers and validating new parts. However, this process still can be time consuming.

We can't just throw in a new component and say, let's see if it works. We've got to really do all the proper life testing and check through. So that's why it doesn't happen overnight, Douglas said.

ResMed currently has an estimated 12- to 18-month backlog with patients waiting anywhere between one or eight weeks for a device depending on their location and the flow of products, Farrell said. The company isn't sharing a 2023 guidance yet on the recall.

The patients are there. And I think it's awful that somebody might have to wait four weeks or eight weeks. I don't want them to wait more than four to eight hours, Farrell said. But right at the moment, we're in this situation; [it] will be that way for a period of time given these unprecedented circumstances.

Other medtech companies also called out challenges in filling orders due to supply chain issues. Baxter International lowered its forecast for revenue and earnings per share for 2022, with CFO Jay Saccaro citing one of the most complicated supply chain environments I have personally seen.

Saccaro broke down the earnings forecast for adjusted earnings before special items, which would decrease from $4.25 to $4.35 per diluted share to $4.12 to $4.20, as follows:

The war in Ukraine, coupled with an already fraught supply chain, creates very significant short-term factors impacting our performance, Saccaro said. Do I think we'll be talking about supply chain in two years? I certainly hope not, nor do I expect that that will be the case. But at least for the next nine months as we see it there will be continued pressure on the supply chain.

CEO Joe Almeida added that the companys backlog is at an all-time high as it is seeing strong demand for its products. Still, sometimes it struggles to fulfill all of that demand because of the ongoing shortage of chips and microprocessors.

Stryker, which has benefited overall from a rebound in procedures across its medsurg, neurotechnology, ortho and spine segments, still saw a slowdown in placements of its Mako surgical robots because of supply chain and hospital staffing shortages. Each of its segments posted an increase in sales year over year, except for other orthopaedics, which dropped 20% because of the slower installations.

CEO Kevin Lobo told investors on Thursday that hospital liquidity is still very strong and that Stryker had double-digit growth in orders in the first quarter.

Large capital has been disrupted partially because of shortages of primarily electronics but also hospitals' ability to actually receive the capital either because of short staffing or because some of their construction projects were delayed, Lobo said of the Mako placements.

Source: Stryker's first quarter earnings report

Abiomed, which makes a line of heart pumps for patients with coronary artery disease and an extracorporeal membrane oxygenation (ECMO) device for patients with respiratory failure, also mentioned labor shortages. The company noted that patient volumes were their lowest in January.Still,volumes picked up in February and March, CFO Todd Trapp said, given that these patients arent truly elective, resulting in a 12% revenue increase for the company in the quarter compared to 2021.

In addition, Edwards Lifesciences, which reported earnings on April 26, also cautioned that hospitals havent fully recovered from the pandemic, although the company still beat analysts estimates for revenue and earnings. CEO Michael Mussallem pointed to a significant labor crunch, partially because of workforce turnover and positions that have yet to be filled.

Keybanc analysts pointed to a mixed picture from the companies that have reported so far in the first quarter.

Positively, procedural volume trends have been exceeding expectations and accelerating into March/April for most regions, excluding China, they wrote in an April 26 research note. However, supply chain constraints are a limiting factor in capital equipment causing some shipping delays, particularly [at the] end of March. Broadly, underlying demand remains healthy and there is optimism on catch-up through the remainder of 2022.

While most of the companies that have reported so far expect to see procedures increase going into the next quarter, some expect slower growth compared to last year. This is partly because the spring of 2021 saw a surge in procedures compared to 2020 and COVID-19 cases had hit a low point after vaccines were rolled out.

Here are a few earnings calls to watch this week:

Ricky Zipp contributed reporting.

More here:

Earnings week 2: Supply chain shortages slowed ResMed, other medtechs from meeting demand - MedTech Dive

Neurable CEO Ramses Alcaide has a mission: bring neurotechnology out of research labs and surgical suites and into everyday life.

Neurable exists to make brain-computer interfaces an everyday thing, Alcaide says.

He envisions a future where the neurotechnology that allows Neurables products to read brainwaves via electrical signals without surgical implants is used to track cognitive capability and mental health, like a Fitbit for the brain.

The company is also building towards a future where brain-computer interfaces (BCI) allow people with disabilities to easily control prosthetics and robotics, and even lets people who cannot speak communicate again.

Their current device, still only available as a preorder, is a set of headphones, called Enten. The headphones are designed to read electrical signals produced by neurons in your brain, a technique called electroencephalography, or EEG for short.

In an EEG, tiny electrodes usually placed directly on the scalp in the lab, but in the ear cups of the Enten headphones pick up the minute electrical charges made by your neurons firing.

Neurable claims that the EEG sensors inside the normal-looking headphones ear cups can detect brain activity, which its proprietary algorithms named after Pokemon can read, analyze, and decode. The idea is to provide insights in focus and neural activity from, and for, people in daily life.

The app might note that a person tends to focus more when listening to certain playlists, for example, and recommend queuing those up right before a deadline, Freethinks Kristin Houser previously reported. If it notices they tend to lose focus about an hour before lunch, it might recommend eating earlier to stave off the slump.

But Alcaides goal is broader than helping you optimize your focus; it is mainstreaming BCI technology in the everyday world.

At its core, the idea of BCI is to use the brains electrical signals to communicate directly with an outside device a machine, an app, or some kind of a computer. BCI allows you to move a robots hand to the left, say, by merely thinking of moving the hand slightly to the left.

While the tech has a distinctly sci-fi feeling to it, BCI is not only quite real, but has been actively researched for half a century.

However, the brain is extremely complicated, and our current understanding of it is limited its a gray box, at best. And since many forms of BCI still require implanted neurotechnology, its hard to imagine many people signing up for surgery in (or even near) the brain for any kind of elective reason.

Noninvasive neurotechnology, like the Enten, is likely to be an important step to feasibility and marketability.

BCI research began in earnest in the early 1970s in the lab of UCLAs Jacques Vidal, according to the Mayo Clinic. Vidal coined the term in a paper published in 1973, and he is broadly considered the founder of the field.

Studies in animals, including non-human primates, continued throughout the 1970s; by the end of the decade, human subjects were able to demonstrate BCI by moving an image of a rocket up and down on a screen.

Research in 2006 showed that neurotechnology implanted into the motor cortex of a man with a spinal injury allowed him to operate a television and a prosthetic hand, as well as move a robotic arm.

Directly implanting neurotechnology in the brain allows researchers to place electrodes right where theyre needed and ensure they get a strong, constant signal. But by definition, they require surgery via specialized equipment and highly trained personnel, making them expensive and risky.

BCI that uses neurotechnology positioned on the skull, rather than inside it, opens up the door for wider adoption.

In 2011, researchers demonstrated the potential for noninvasive neurotechnology, using EEG-powered BCI to spell words on a computer screen, and research on both implanted and non-implanted options has continued apace. BCI neurotechnology is now allowing people to translate thoughts into text, control exoskeletons to help rehab hands, and you can even find open-source options.

Neurable is not the only company trying to bring neurotechnology to everyday life. Most boisterous is Elon Musks Neuralink, whose efforts to develop commercially-available invasive nanotechnology have met with measured response from neuroscientists (and controversy from animal rights groups).

Musks chip-implanted pigs showed that Neuralinks tech appears to be where the field has been for decades the ability to see neurons firing and hear the sounds of a brain at work. But his ability to market cutting-edge tech, as seen with Tesla and SpaceX, makes the idea of commercially available Neuralink implants (someday, for some purpose) hard to write off as complete fantasy.

Closer to Neurable are other EEG products like Muse. Marketed as a meditation, sleep, and focus enhancement device, Muse utilizes a similar technology to Neurable, albeit in headband form.

As researchers continue to learn more about the brain and neurotechnology including not only the hardware, but the algorithms needed to make sense of all that brain data continues to improve, it is possible that Neuralink founder Alcaides vision may indeed come to pass.

For Alcaide and Neurable, opening that technology to the world is really why we exist.

Here is the original post:

Mind-reading technology Are we ready for it? - Freethink

It appeared under the Twitter handle of Dr Thomas Oxley; a neurologist and CEO of Australian neurotechnology company, Synchron.

But the tweet didnt come from Dr Oxley it was instead streamed directly from the brain of a man named Philip OKeefe, 62, living in regional Victoria.

My hope is that I'm paving the way for people to tweet through thoughts phil Philip added in a follow-up message.

Hi Philip, how do you control which thoughts are typed? one Twitter user replied.

Amazing. Hello Matrix, wrote another.

In May of that year, Philip was diagnosed with motor neurone disease (MND), a terminal and progressive disease that attacks the nerves in the brain and spinal cord, with respiratory muscle weakness occurring eventually in everyone with the disease.

One of the first things that I lost was my fine motor skills. The ability to hold a pen, type on the keyboard, tap on a phone is very, very limited, Philip told Insight.

Communication to the outside world is disappearing.

A photo of Philip O'Keefe and his family.

He jumped at the opportunity to be of any assistance given his terminal outcome, Philips wife Trish told Insight.

Philip was only the second person in the world to be implanted with the technology, and the trial came with risks.

The actual operation or procedure could be life-threatening at the time, Trish said.

Philips device, called the Stentrode device, reads his brain signals and transmits them to a computer.

The technology is called the Stentrode device and is inserted into a vein that sits just under the skull at the top of his head. The technology reads Philips brain signals and wirelessly transmits them to a computer which then turns them into commands on the screen, such as click and drag.

Hes been able to send texts, emails and scroll the web using just the power of his thoughts. And, in the process, restore some of the independence stolen by his MND.

We were awestruck. We thought it was AI and something out of Star Trek, Trish told Insight.

The technology Philip is using falls under an umbrella term of BCI, or brain computer interface.

With this investment will come more human clinical trials, and whilst Philips experience has been overwhelmingly positive, its not always the case for everyone who merges their brain with technology.

I've ended up with a lot of bruising on my legs. I rolled my shoulder out. My brain just wasn't working as well as it should be, she said.

In the process, its stolen her ability to do other things she loved in life, like dancing.

Hannahs epilepsy prevented her from pursuing her passions, like ballet.

Her implant was developed to read her neural activity to predict when she was about to have a seizure.

Scientifically, the trial was successful. But because the technology was so accurate, it discovered that Hannah was having over 100 seizures a day.

Hannah after the operation to implant a device in her brain.

I would constantly have this bright red light going off, she told Insight.

I kept getting the red, brighter and brighter.

Hannah had often tried to hide her epilepsy in her younger years, and now this technology was reminding her up to 100 times a day of when she was having a seizure.

It played with my mind so much.

Frederic Gilbert, a bio-ethicist from the University of Tasmania who interviews people with technology implanted in their brains as part of his research, says Hannahs case raises some of the complicated questions that come with merging the human brain with technology.

We have observed that even if the technology is successful, effective and working perfectly well, there can be psychological rejection, he told Insight.

You have a loss of agency.

With the brain something as central for someone's identity, sense of their self I think, it would be quite crucial to have ethics involved early, as soon as possible.

As technology advances, further trials commence, and more people altruistically put their brains on the line for science, Frederic notes that: I think the line we need to walk is keeping humans the priority.

A photo of Philip O'Keefe and his wife Trish on their wedding day.

Its a start. Just the start, of a very big journey, Philip said.

For Hannah, she would never want another piece of technology implanted in her brain.

The solution for her is a peaceful life, technology-free and immersed in the beauty of Tasmania. She still has her very bad seizures.

But they're just the bad parts of your day. Nothing more than that.

Watch Insight's episode on

Continue reading here:

The brain implant that can translate your thoughts into text - SBS News

Medical device manufacturer Stryker will layoff 88 people by the end of Mayas part of a previously announced plan to close its Lakeland location by December 2023 and let go of495workers.

Stryker Employment CompanyLLC, in an April 1 letter,notified Mayor Bill Mutz that it had decided to continue its program of layoffs at the company's Lakeland facility.

"We expect that this will result in the permanent layoff of approximately 495 employees and the closure of the facility by Dec. 31, 2023," said the letter signed by Stryker'shuman resources manager, Kathy C. Taylor.

The Michigan-based company started the layoff with the elimination of 22 positions on Dec. 31, the letter said. Stryker plans to eliminate an additional 88 positions on May 31.

The remaining 385job cuts are expected on a rolling basis byDec. 31, 2023, Taylor said.

Previously: Stryker to lay off 500, close Lakeland office by December 2023

Lakeland warehouse: Amid global cost-cutting plan, Peloton to close local facility, laying off 58

Local job growth: February job figures show Polk County still ahead of Florida in many job categories

The letter was sent to meet federally mandated Worker Adjustment Retraining and Notification Act requirements, she said.

The companyfirst announced the layoffs in an October letter to the state.

Stryker makes orthopedics, medical and surgical and neurotechnology and spine products for hospital patients. With numerous U.S. and worldwidesubsidiaries, Stryker has about 46,000 employees worldwide, andits 2021 sales increased19.2% from the previous year to $17.1 billion.

It sells medical devices in 100 countries.

Since the layoffs were announced, the Stryker's publicly traded stock has average more than $270 in price. Its 52-week range has been from$236to$281.

See the rest here:

Stryker says 88 jobs to be eliminated in May, part of previously announced layoff schedule - The Ledger

Moon Rabbit has been at the forefront for over 30 years in developing new technologies and massively enhancing the human condition. Consisting of reputed scientists from Neurotech, Computation, Biotech, Nanotech, and even Space, the company uses a combination of neurotechnology, molecular machines, and space computer programs. Foresight Institute is a leading research giant that has made cutting-edge progress in brain-computer interfaces, asteroid mining, private ML, and finally, longevity.

The partnership aligns Moon Rabbit in a perfect position to assign research funding and grants to make possible the goals of removing every known life-threatening condition known to man, more specifically, aging. The crypto conglomerate is synergizing its efforts with Foresight Institute and is offering young and bright minds to accelerate their career and ideas. Foresight Institute is making giant strides in biotechnology and molecular machine nanotechnology. The company has excelled in restraining recklessness and creating communities to augment the positive uses of these technologies and decrease the accidental misuse of their life-saving technologies.

Angel Versetti, Founder of Moon Rabbit, is a pioneer in the experimental direction of prolonging longevity. The central theme of Moon Rabbit is to ensure that access to longevity solutions is democratized in creating a decentralized ecosystem and providing the required space for the maturation of these projects. Similarly, Foresight is well ahead in the competitor arena and is well known for quick integration with Web 3 technologies.

By aligning with the core competencies of the Moon Rabbit, the Frontier Institute aims to leverage blockchain technology for making rapid advances in the fields of crowdsourcing, crowdfunding, and ensuring liquidity access with complete scalability.

Angel Versetti opines that once the limitations of the financial world are conquered, the teams will challenge the bigger problems in society.

The new buzzword in the corporate world is longevity, with the world-famous crypto millionaires using their vast financial resources in propelling longevity research.

Moon Rabbit is the pathbreaking cryptocurrency in this world to pursue the dream of eternal life. This brand is a part of Polkadot, which enjoys end-to-end cross-chain interoperability. Contributing to life extension research is in full force in the AAA ecosystem, leading to creating a space where non-stop scientific cooperation is possible. The partnership between these two companies will enhance research collaboration in the longevity arena and aims to reward outstanding performers.

Moon Rabbit is a pioneering crypto conglomerate company aiming to unite distributed ledgers and form the ultimate cross-chain protocols known as the Meta chains. Web 3 and cryptos are short-term foundations and the perfect instrument to achieve the Grand Mission of unlocking the secrets of eternal life.

See the original post here:

Moon Rabbit Collaborates with Foresight Institute to Speed Up Life Extension Research - CryptoNewsZ

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing Psychedelics to TherapeuticsTM, today announced that the first study visit has been conducted in a Cybin-sponsored feasibility study evaluating Kernels quantitative neuroimaging technology, Flow, to measure ketamines psychedelic effects on cerebral cortex hemodynamics.

The commencement of the Kernel feasibility study marks a truly exciting moment, not only for Cybin and Kernel, but also for the entire field of psychedelic drug development. To this point, studies have had to rely on subjective patient reporting. By deploying the innovative Flow technology, this is the first time any company has had the ability to collect and quantify longitudinal brain activity before, during and after a psychedelic experience. We are specifically encouraged by this scientific advancement as it has the potential for Cybin to collect real-time quantitative data for our promising psychedelic-based therapies. These data will support the Companys leading research position as we move our important treatment options through regulatory discussions and late-stage clinical development, said Doug Drysdale, Chief Executive Officer of Cybin.

Kernel Flow is a groundbreaking neuroimaging technology that enables rigorous characterization and quantification of physiological processes in the human brain. Our collaboration with Cybin has the potential to significantly enhance the research evaluating the potential positive effects of psychedelic therapies on the brain to improve mental wellness, said Bryan Johnson, Founder and Chief Executive Officer of Kernel.

About the Feasibility Study:

The main objective of the Company-sponsored feasibility study is to evaluate a participants experience wearing Kernel Flow while in an altered state of consciousness following the administration of ketamine. Participants will receive either a low dose of ketamine or placebo while wearing the Flow headset, which is equipped with hi-tech sensors to record brain activity and will report their experience using structured questionnaires and validated assessments during study visits and at follow-up. The four-week study will also evaluate brain activity before and after administrating the study agents - low-dose ketamine or placebo.

The feasibility study received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) authorization in October 2021 and Institutional Review Board (IRB) approval in January 2022.

As part of Cybins sponsorship of the feasibility study, the Company will retain an exclusive interest in any innovations that are discovered or developed through its independent analysis of the study findings.

About Kernel Flow

Kernel Flow is a wearable headset that measures brain activity by recording local changes in blood oxygenation. It is adjustable, can accommodate nearly anyone and is safe. Kernel Flow is groundbreaking neurotechnology because it reduces loud, expensive, and room-sized equipment to a head-worn apparatus while providing neural activity data of the highest possible optical quality. This combination has never existed in such a commercial and scalable device, all factors for why brain interfaces and neuroimaging technology has largely remained in academic labs or hospital basements and why mental health diagnosis and treatment have behavioral, instead of biomarker, endpoints. The entire system is the size and look of a bicycle helmet and could, in the future, be more broadly used for neuroscientific or physiological studies of brain activity during psychedelic use.

About Cybin

Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, United Kingdom and Ireland. The Company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.

Cautionary Notes and Forward-Looking Statements

Certain statements in this press release constitute forward-looking information. All statements other than statements of historical fact contained in this press release, including, without limitation, statements regarding Cybins future, strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words believe, expect, aim, intend, plan, continue, will, may, would, anticipate, estimate, forecast, predict, project, seek, should or similar expressions or the negative thereof, are forward-looking statements. Forward-looking statements in this news release include statements regarding the Companys proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens, including the anticipated results of using Kernel Flow technology, to potentially treat psychiatric disorders.

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: implications of the COVID-19 pandemic on the Companys operations; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; and the risk factors set out in the Company's management's discussion and analysis for the period ended December 31, 2021 and the Company's listing statement dated November 9, 2020, which are available under the Company's profile on http://www.sedar.com and with the U.S. Securities and Exchange Commission on EDGAR at http://www.sec.gov. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

Cybin makes no medical, treatment or health benefit claims about Cybins proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybins performance and operations.

Neither the Neo Exchange Inc. nor the NYSE American LLC stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.

Read more from the original source:

Cybin Announces Initiation of Kernel Flow Feasibility Study Measuring Psychedelic Effects on the Brain - Business Wire